“My goal is straightforward: to have an unprecedented impact on alleviating human suffering,” states Lou Reese, co-founder of Vaxxinity. If successful, the biotechnology company aims to introduce a groundbreaking drug by 2030 that could transform the approach to Alzheimer’s disease and potentially lead to its eradication.
Alzheimer’s, the most prevalent type of dementia, inflicts immense hardship on patients and their families. This and other dementia forms are increasingly viewed as a looming crisis for the aging global population.
However, a potential solution may be on the horizon. Vaxxinity, located in Cape Canaveral, Florida, is developing vaccines aimed at halting the progression of Alzheimer’s disease or even preventing its onset altogether. Alongside other innovators in the field, this approach shows significant promise. “We are entering a period where the relentless advance of Alzheimer’s disease might be prevented,” notes a prominent neuroscientist.
Currently, around 55 million individuals are affected by dementia, a figure expected to reach approximately 140 million by 2050. This increase poses serious implications for patients, families, and health care systems worldwide.
